Barclays PLC Has $330,000 Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Barclays PLC lowered its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.2% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 54,563 shares of the medical instruments supplier’s stock after selling 2,993 shares during the period. Barclays PLC owned approximately 0.07% of OraSure Technologies worth $330,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in OSUR. Advisor Group Holdings Inc. raised its position in OraSure Technologies by 12.0% in the first quarter. Advisor Group Holdings Inc. now owns 20,720 shares of the medical instruments supplier’s stock worth $163,000 after purchasing an additional 2,225 shares in the last quarter. Legal & General Group Plc grew its stake in OraSure Technologies by 1.8% during the fourth quarter. Legal & General Group Plc now owns 177,227 shares of the medical instruments supplier’s stock worth $854,000 after buying an additional 3,168 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in OraSure Technologies by 27.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,184 shares of the medical instruments supplier’s stock worth $73,000 after buying an additional 3,313 shares during the last quarter. Brinker Capital Investments LLC grew its stake in OraSure Technologies by 5.2% during the first quarter. Brinker Capital Investments LLC now owns 78,023 shares of the medical instruments supplier’s stock worth $529,000 after buying an additional 3,881 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in OraSure Technologies by 5.5% during the third quarter. Thrivent Financial for Lutherans now owns 75,067 shares of the medical instruments supplier’s stock worth $284,000 after buying an additional 3,883 shares during the last quarter. Institutional investors and hedge funds own 88.76% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on OSUR. StockNews.com raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. TheStreet cut shares of OraSure Technologies from a “c” rating to a “d+” rating in a research note on Friday, August 4th. Finally, Stephens decreased their price target on shares of OraSure Technologies from $6.50 to $5.00 in a research note on Monday, July 17th.

OraSure Technologies Price Performance

OSUR opened at $6.87 on Thursday. The company’s 50 day simple moving average is $5.41 and its 200-day simple moving average is $5.85. OraSure Technologies, Inc. has a one year low of $3.45 and a one year high of $7.82. The stock has a market capitalization of $504.40 million, a P/E ratio of 11.85 and a beta of 0.08.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). OraSure Technologies had a net margin of 9.01% and a return on equity of 11.58%. The business had revenue of $85.44 million during the quarter, compared to analyst estimates of $64.30 million. As a group, analysts anticipate that OraSure Technologies, Inc. will post 0.31 EPS for the current year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions.